{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:35Z","timestamp":1792788455873,"version":"4.5.0"},"reference-count":213,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700306"],"award-info":[{"award-number":["81700306"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2026JJ50095"],"award-info":[{"award-number":["2026JJ50095"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013277","name":"National Clinical Key Specialty Project Foundation","doi-asserted-by":"publisher","award":["Z2023006"],"award-info":[{"award-number":["Z2023006"]}],"id":[{"id":"10.13039\/501100013277","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0528200"],"award-info":[{"award-number":["2024ZD0528200"]}]},{"name":"Innovation Platform and Talent Program","award":["2023TP1047"],"award-info":[{"award-number":["2023TP1047"]}]},{"name":"Scientific Research Project of the Education Department of Hunan Province","award":["25A0335"],"award-info":[{"award-number":["25A0335"]}],"id":[{"id":"https:\/\/ror.org\/05ckg3w11","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015921","name":"Hengyang Science and Technology Board","doi-asserted-by":"publisher","award":["202550038088"],"award-info":[{"award-number":["202550038088"]}],"id":[{"id":"10.13039\/501100015921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sodium-glucose cotransporter 2 (SGLT2) is a low-affinity, high-capacity transporter expressed predominantly in the renal proximal tubule, where it mediates the sodium-coupled reabsorption of most filtered glucose. SGLT2 inhibitors have evolved from glucose-lowering agents into disease-modifying therapies across the cardio-renal-metabolic continuum. Blockade of proximal tubular transport induces glycosuria, osmotic diuresis, restoration of tubuloglomerular feedback, resetting of renal haemodynamics, and altered fluid compartmentalisation. These early renal and circulatory effects interact with systemic metabolic adaptations, including pseudo-starvation signalling, erythropoiesis, altered uric acid handling, and changes in substrate availability. At the cellular level, SGLT2 inhibition has been linked to improved ionic homeostasis and mitochondrial quality control, reduced oxidative stress, modulation of inflammation, and attenuation of maladaptive tissue remodelling. Endothelial injury may connect these cellular effects with microvascular dysfunction and fibrosis. Endothelial dysfunction and endothelial-to-mesenchymal transition (EndMT) offer a mechanistic framework for understanding the relationship between microvascular injury and fibrosis. However, EndMT is best viewed as one component of a broader endothelial\u2013stromal stress response rather than as a single proven mediator of clinical benefit. These pharmacodynamic and cellular effects help explain the consistent clinical efficacy of SGLT2 inhibitors across type 2 diabetes, chronic kidney disease, and heart failure (HF), while also informing emerging applications in acute HF, after myocardial infarction, and in patients with arrhythmia or metabolic dysfunction-associated steatohepatitis. This Review integrates mechanistic, pharmacological, and clinical evidence to identify unresolved translational gaps and future directions, including mechanism-informed biomarkers, imaging, spatial multi-omics, phenotype-guided patient stratification, dual sodium-glucose cotransporter 1\/2 inhibition, and rational combination therapy.<\/jats:p>","DOI":"10.1186\/s43556-026-00604-3","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:53:41Z","timestamp":1790762021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications"],"prefix":"10.1186","volume":"7","author":[{"given":"Xue-Ting","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Yi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Heng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Liang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Fang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Sheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3842-1666","authenticated-orcid":false,"given":"Heng-Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"7","key":"604_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrd3180","volume":"9","author":"EC Chao","year":"2010","unstructured":"Chao EC, Henry RR. SGLT2 inhibition\u2013a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551\u20139. https:\/\/doi.org\/10.1038\/nrd3180.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"604_CR2","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.34067\/KID.0002772021","volume":"2","author":"EM Wright","year":"2021","unstructured":"Wright EM. SGLT2 inhibitors: physiology and pharmacology. Kidney360. 2021;2(12):2027\u201337. https:\/\/doi.org\/10.34067\/KID.0002772021.","journal-title":"Kidney360"},{"issue":"5","key":"604_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","volume":"120","author":"A Preda","year":"2024","unstructured":"Preda A, Montecucco F, Carbone F, Camici GG, L\u00fcscher TF, Kraler S, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024;120(5):443\u201360. https:\/\/doi.org\/10.1093\/cvr\/cvae047.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"604_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12(7):447\u201361. https:\/\/doi.org\/10.1016\/S2213-8587(24)00102-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10365","key":"604_CR5","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8.","journal-title":"Lancet"},{"issue":"20","key":"604_CR6","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606\u201335. https:\/\/doi.org\/10.1161\/CIR.0000000000001184.","journal-title":"Circulation"},{"issue":"11","key":"604_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/jamacardio.2023.3241","volume":"8","author":"JW Ostrominski","year":"2023","unstructured":"Ostrominski JW, Arnold SV, Butler J, Fonarow GC, Hirsch JS, Palli SR, et al. Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 1999\u20132020. JAMA Cardiol. 2023;8(11):1050\u201360. https:\/\/doi.org\/10.1001\/jamacardio.2023.3241.","journal-title":"JAMA Cardiol"},{"issue":"21","key":"604_CR8","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1001\/jama.2024.6892","volume":"331","author":"R Aggarwal","year":"2024","unstructured":"Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020. JAMA. 2024;331(21):1858\u201360. https:\/\/doi.org\/10.1001\/jama.2024.6892.","journal-title":"JAMA"},{"issue":"3","key":"604_CR9","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1.","journal-title":"Nat Med"},{"issue":"4","key":"604_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","volume":"148","author":"M Packer","year":"2023","unstructured":"Packer M, Wilcox CS, Testani JM. Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes. Circulation. 2023;148(4):354\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064346.","journal-title":"Circulation"},{"issue":"24","key":"604_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI187097","volume":"134","author":"JH Berger","year":"2024","unstructured":"Berger JH, Finck BN. Beyond ketosis: the search for the mechanism underlying SGLT2-inhibitor benefit continues. J Clin Invest. 2024;134(24):e187097. https:\/\/doi.org\/10.1172\/JCI187097.","journal-title":"J Clin Invest"},{"issue":"6","key":"604_CR12","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ekir.2024.02.1435","volume":"9","author":"SA Lee","year":"2024","unstructured":"Lee SA, Riella LV. Narrative review of immunomodulatory and anti-inflammatory effects of sodium-glucose cotransporter 2 inhibitors: unveiling novel therapeutic frontiers. Kidney Int Rep. 2024;9(6):1601\u201313. https:\/\/doi.org\/10.1016\/j.ekir.2024.02.1435.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"604_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164486","volume":"133","author":"JA Schaub","year":"2023","unstructured":"Schaub JA, AlAkwaa FM, McCown PJ, Naik AS, Nair V, Eddy S, et al. SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes. J Clin Invest. 2023;133(5):e164486. https:\/\/doi.org\/10.1172\/JCI164486.","journal-title":"J Clin Invest"},{"issue":"1","key":"604_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ejhf.2066","volume":"23","author":"EM Boorsma","year":"2021","unstructured":"Boorsma EM, Beusekamp JC, Ter Maaten JM, Figarska SM, Danser AHJ, van Veldhuisen DJ, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. Eur J Heart Fail. 2021;23(1):68\u201378. https:\/\/doi.org\/10.1002\/ejhf.2066.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"604_CR15","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1111\/dom.15183","volume":"25","author":"M J\u00fcrgens","year":"2023","unstructured":"J\u00fcrgens M, Schou M, Hasbak P, Kjaer A, Wolsk E, Zerahn B, et al. The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes. Diabetes Obes Metab. 2023;25(10):2888\u201396. https:\/\/doi.org\/10.1111\/dom.15183.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"604_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1681\/ASN.0000000000000271","volume":"35","author":"KJ Mayne","year":"2024","unstructured":"Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, et al. Effects of empagliflozin on fluid overload, weight, and blood pressure in CKD. J Am Soc Nephrol. 2024;35(2):202\u201315. https:\/\/doi.org\/10.1681\/ASN.0000000000000271.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"604_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","volume":"140","author":"K Kidokoro","year":"2019","unstructured":"Kidokoro K, Cherney DZI, Bozovic A, Nagasu H, Satoh M, Kanda E, et al. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation. 2019;140(4):303\u201315. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037418.","journal-title":"Circulation"},{"issue":"4","key":"604_CR18","doi-asserted-by":"publisher","first-page":"C951","DOI":"10.1152\/ajpcell.00528.2022","volume":"324","author":"X Chen","year":"2023","unstructured":"Chen X, Deli\u0107 D, Cao Y, Shen L, Shao Q, Zhang Z, et al. Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system. Am J Physiol Cell Physiol. 2023;324(4):C951\u201362. https:\/\/doi.org\/10.1152\/ajpcell.00528.2022.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"8","key":"604_CR19","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/dom.14411","volume":"23","author":"AB van der Aart-van der Beek","year":"2021","unstructured":"van der Aart-van der Beek AB, Cherney D, Laverman GD, Stefansson B, van Raalte DH, Hoogenberg K, et al. Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: an analysis of three randomized controlled trials. Diabetes Obes Metab. 2021;23(8):1961\u20137. https:\/\/doi.org\/10.1111\/dom.14411.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"604_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2215\/CJN.0000000889","volume":"21","author":"P Bjornstad","year":"2026","unstructured":"Bjornstad P, Danne T, Klingensmith GJ, Schueler E, Tartakovsky I, Marquard J, et al. Impact of empagliflozin on glomerular hyperfiltration and albuminuria in youth with type 2 diabetes: post hoc analysis of DINAMO. Clin J Am Soc Nephrol. 2026;21(2):273\u201382. https:\/\/doi.org\/10.2215\/CJN.0000000889.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"604_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.kint.2021.10.037","volume":"101","author":"J Zhang","year":"2022","unstructured":"Zhang J, Cai J, Cui Y, Jiang S, Wei J, Kim YC, et al. Role of the macula densa sodium glucose cotransporter type 1-neuronal nitric oxide synthase-tubuloglomerular feedback pathway in diabetic hyperfiltration. Kidney Int. 2022;101(3):541\u201350. https:\/\/doi.org\/10.1016\/j.kint.2021.10.037.","journal-title":"Kidney Int"},{"issue":"24","key":"604_CR22","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1161\/CIRCULATIONAHA.122.061033","volume":"146","author":"RA Scholtes","year":"2022","unstructured":"Scholtes RA, Hesp AC, Mosterd CM, Geurts F, Hoorn EJ, Touw DJ, et al. Kidney hemodynamic effects of angiotensin receptor blockade, sodium-glucose cotransporter-2 inhibition alone, and their combination: a crossover randomized trial in people with type 2 diabetes. Circulation. 2022;146(24):1895\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061033.","journal-title":"Circulation"},{"key":"604_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.982722","volume":"13","author":"H Kroeger","year":"2022","unstructured":"Kroeger H, Kessel F, Sradnick J, Todorov V, Gembardt F, Hugo C. Intravital imaging of hemodynamic glomerular effects of enalapril or\/and empagliflozin in STZ-diabetic mice. Front Physiol. 2022;13:982722. https:\/\/doi.org\/10.3389\/fphys.2022.982722.","journal-title":"Front Physiol"},{"issue":"2","key":"604_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","volume":"9","author":"J Jensen","year":"2021","unstructured":"Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, K\u00f8ber L, et al. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2021;9(2):106\u201316. https:\/\/doi.org\/10.1016\/S2213-8587(20)30382-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"604_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009156","volume":"15","author":"M Omar","year":"2022","unstructured":"Omar M, Jensen J, Burkhoff D, Frederiksen PH, Kistorp C, Videb\u00e6k L, et al. Effect of empagliflozin on blood volume redistribution in patients with chronic heart failure and reduced ejection fraction: an analysis from the empire HF randomized clinical trial. Circ Heart Fail. 2022;15(3):e009156. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.009156.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"604_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-020-01175-5","volume":"20","author":"M Rau","year":"2021","unstructured":"Rau M, Thiele K, Hartmann N-UK, Schuh A, Altiok E, M\u00f6llmann J, et al. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Cardiovasc Diabetol. 2021;20(1):6. https:\/\/doi.org\/10.1186\/s12933-020-01175-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"604_CR27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2337\/db21-0721","volume":"71","author":"E Wolsk","year":"2022","unstructured":"Wolsk E, J\u00fcrgens M, Schou M, Ersb\u00f8ll M, Hasbak P, Kj\u00e6r A, et al. Randomized controlled trial of the hemodynamic effects of empagliflozin in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE trial. Diabetes. 2022;71(4):812\u201320. https:\/\/doi.org\/10.2337\/db21-0721.","journal-title":"Diabetes"},{"issue":"17","key":"604_CR28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation. 2021;143(17):1673\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052503.","journal-title":"Circulation"},{"issue":"1","key":"604_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41581-020-00350-x","volume":"17","author":"A Marton","year":"2021","unstructured":"Marton A, Kaneko T, Kovalik J-P, Yasui A, Nishiyama A, Kitada K, et al. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol. 2021;17(1):65\u201377. https:\/\/doi.org\/10.1038\/s41581-020-00350-x.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"604_CR30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","volume":"141","author":"CD Mazer","year":"2020","unstructured":"Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, et al. Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2020;141(8):704\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044235.","journal-title":"Circulation"},{"issue":"4","key":"604_CR31","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1210\/clinem\/dgaa057","volume":"105","author":"H Ghanim","year":"2020","unstructured":"Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, et al. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab. 2020;105(4):e1056\u201363. https:\/\/doi.org\/10.1210\/clinem\/dgaa057.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"604_CR32","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1111\/dom.14517","volume":"23","author":"K Thiele","year":"2021","unstructured":"Thiele K, Rau M, Hartmann N-UK, M\u00f6llmann J, Jankowski J, B\u00f6hm M, et al. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: data from a randomized, placebo-controlled study. Diabetes Obes Metab. 2021;23(12):2814\u20138. https:\/\/doi.org\/10.1111\/dom.14517.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"604_CR33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20(3):479\u201387. https:\/\/doi.org\/10.1111\/dom.13126.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"604_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","volume":"148","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Reddy YNV, Braun A, Sorimachi H, Omar M, Popovic D, et al. Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Circulation. 2023;148(10):834\u201344. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065134.","journal-title":"Circulation"},{"issue":"7","key":"604_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.164296","volume":"8","author":"A Kogot-Levin","year":"2023","unstructured":"Kogot-Levin A, Riahi Y, Abramovich I, Mosenzon O, Agranovich B, Kadosh L, et al. Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition. JCI Insight. 2023;8(7):e164296. https:\/\/doi.org\/10.1172\/jci.insight.164296.","journal-title":"JCI Insight"},{"issue":"3","key":"604_CR36","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"M Packer","year":"2020","unstructured":"Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508\u201311. https:\/\/doi.org\/10.2337\/dci19-0074.","journal-title":"Diabetes Care"},{"issue":"7","key":"604_CR37","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME trial: a \u201cThrifty Substrate\u201d hypothesis. Diabetes Care. 2016;39(7):1108\u201314. https:\/\/doi.org\/10.2337\/dc16-0330.","journal-title":"Diabetes Care"},{"issue":"15","key":"604_CR38","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.056.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"604_CR39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.123.015298","volume":"16","author":"CG Santos-Gallego","year":"2023","unstructured":"Santos-Gallego CG, Requena-Ib\u00e1\u00f1ez JA, Picatoste B, Fardman B, Ishikawa K, Mazurek R, et al. Cardioprotective effect of empagliflozin and circulating ketone bodies during acute myocardial infarction. Circ Cardiovasc Imaging. 2023;16(4):e015298. https:\/\/doi.org\/10.1161\/CIRCIMAGING.123.015298.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"604_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12933-024-02221-2","volume":"23","author":"F Aziz","year":"2024","unstructured":"Aziz F, Tripolt NJ, Pferschy PN, Scharnagl H, Abdellatif M, Oulhaj A, et al. Ketone body levels and its associations with cardiac markers following an acute myocardial infarction: a post hoc analysis of the EMMY trial. Cardiovasc Diabetol. 2024;23(1):145. https:\/\/doi.org\/10.1186\/s12933-024-02221-2.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"604_CR41","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.122.060402","volume":"146","author":"S Selvaraj","year":"2022","unstructured":"Selvaraj S, Fu Z, Jones P, Kwee LC, Windsor SL, Ilkayeva O, et al. Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF. Circulation. 2022;146(11):808\u201318. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060402.","journal-title":"Circulation"},{"issue":"6","key":"604_CR42","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jchf.2024.02.018","volume":"12","author":"S Selvaraj","year":"2024","unstructured":"Selvaraj S, Patel S, Sauer AJ, McGarrah RW, Jones P, Kwee LC, et al. Targeted metabolomic profiling of dapagliflozin in heart failure with preserved ejection fraction: the PRESERVED-HF trial. JACC Heart Fail. 2024;12(6):999\u20131011. https:\/\/doi.org\/10.1016\/j.jchf.2024.02.018.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"604_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.011980","volume":"17","author":"S Selvaraj","year":"2024","unstructured":"Selvaraj S, Patel S, Sauer AJ, McGarrah RW, Jones P, Kwee LC, et al. Metabolic effects of the SGLT2 inhibitor dapagliflozin in heart failure across the spectrum of ejection fraction. Circ Heart Fail. 2024;17(11):e011980. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.124.011980.","journal-title":"Circ Heart Fail"},{"issue":"22","key":"604_CR44","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","volume":"147","author":"MJ Hundertmark","year":"2023","unstructured":"Hundertmark MJ, Adler A, Antoniades C, Coleman R, Griffin JL, Holman RR, et al. Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial. Circulation. 2023;147(22):1654\u201369. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062021.","journal-title":"Circulation"},{"issue":"1","key":"604_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12933-021-01410-7","volume":"20","author":"R Pietschner","year":"2021","unstructured":"Pietschner R, Kolwelter J, Bosch A, Striepe K, Jung S, Kannenkeril D, et al. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol. 2021;20(1):219. https:\/\/doi.org\/10.1186\/s12933-021-01410-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"604_CR46","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","volume":"32","author":"I Tomita","year":"2020","unstructured":"Tomita I, Kume S, Sugahara S, Osawa N, Yamahara K, Yasuda-Yamahara M, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 2020;32(3):404-419.e6. https:\/\/doi.org\/10.1016\/j.cmet.2020.06.020.","journal-title":"Cell Metab"},{"key":"604_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.589273","volume":"12","author":"L Li","year":"2021","unstructured":"Li L, Li Q, Huang W, Han Y, Tan H, An M, et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front Pharmacol. 2021;12:589273. https:\/\/doi.org\/10.3389\/fphar.2021.589273.","journal-title":"Front Pharmacol"},{"issue":"3","key":"604_CR48","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RCI, Fiolet JWT, Stienen GJM, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568\u201373. https:\/\/doi.org\/10.1007\/s00125-016-4134-x.","journal-title":"Diabetologia"},{"issue":"5","key":"604_CR49","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00395-024-01067-9","volume":"119","author":"S Chen","year":"2024","unstructured":"Chen S, Wang Q, Bakker D, Hu X, Zhang L, van der Made I, et al. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2. Basic Res Cardiol. 2024;119(5):751\u201372. https:\/\/doi.org\/10.1007\/s00395-024-01067-9.","journal-title":"Basic Res Cardiol"},{"issue":"22","key":"604_CR50","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","volume":"143","author":"K Philippaert","year":"2021","unstructured":"Philippaert K, Kalyaanamoorthy S, Fatehi M, Long W, Soni S, Byrne NJ, et al. Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143(22):2188\u2013204. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.053350.","journal-title":"Circulation"},{"issue":"13","key":"604_CR51","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/CIRCULATIONAHA.121.057237","volume":"145","author":"B Hegyi","year":"2022","unstructured":"Hegyi B, Mira Hernandez J, Shen EY, Habibi NR, Bossuyt J, Bers DM. Empagliflozin reverses late Na+ current enhancement and cardiomyocyte proarrhythmia in a translational murine model of heart failure with preserved ejection fraction. Circulation. 2022;145(13):1029\u201331. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057237.","journal-title":"Circulation"},{"issue":"9","key":"604_CR52","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/cvr\/cvae095","volume":"120","author":"M Trum","year":"2024","unstructured":"Trum M, Riechel J, Schollmeier E, Lebek S, Hegner P, Reuthner K, et al. Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF. Cardiovasc Res. 2024;120(9):999\u20131010. https:\/\/doi.org\/10.1093\/cvr\/cvae095.","journal-title":"Cardiovasc Res"},{"issue":"24","key":"604_CR53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176708","volume":"134","author":"L Goedeke","year":"2024","unstructured":"Goedeke L, Ma Y, Gaspar RC, Nasiri A, Lee J, Zhang D, et al. SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. J Clin Invest. 2024;134(24):e176708. https:\/\/doi.org\/10.1172\/JCI176708.","journal-title":"J Clin Invest"},{"issue":"11","key":"604_CR54","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.7150\/thno.75121","volume":"12","author":"L Ma","year":"2022","unstructured":"Ma L, Zou R, Shi W, Zhou N, Chen S, Zhou H, et al. SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia\/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways. Theranostics. 2022;12(11):5034\u201350. https:\/\/doi.org\/10.7150\/thno.75121.","journal-title":"Theranostics"},{"issue":"1","key":"604_CR55","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12933-022-01532-6","volume":"21","author":"R Zou","year":"2022","unstructured":"Zou R, Shi W, Qiu J, Zhou N, Du N, Zhou H, et al. Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion injury through improving mitochondrial homeostasis. Cardiovasc Diabetol. 2022;21(1):106. https:\/\/doi.org\/10.1186\/s12933-022-01532-6.","journal-title":"Cardiovasc Diabetol"},{"key":"604_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102288","volume":"52","author":"C Cai","year":"2022","unstructured":"Cai C, Guo Z, Chang X, Li Z, Wu F, He J, et al. Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway. Redox Biol. 2022;52:102288. https:\/\/doi.org\/10.1016\/j.redox.2022.102288.","journal-title":"Redox Biol"},{"issue":"48","key":"604_CR57","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","volume":"42","author":"H Kondo","year":"2021","unstructured":"Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42(48):4947\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehab420.","journal-title":"Eur Heart J"},{"issue":"1","key":"604_CR58","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12933-024-02481-y","volume":"23","author":"FR Alsereidi","year":"2024","unstructured":"Alsereidi FR, Khashim Z, Marzook H, Al-Rawi AM, Salomon T, Almansoori MK, et al. Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived \u03b2 cells. Cardiovasc Diabetol. 2024;23(1):388. https:\/\/doi.org\/10.1186\/s12933-024-02481-y.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"604_CR59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12933-021-01392-6","volume":"20","author":"Z Hu","year":"2021","unstructured":"Hu Z, Ju F, Du L, Abbott GW. Empagliflozin protects the heart against ischemia\/reperfusion-induced sudden cardiac death. Cardiovasc Diabetol. 2021;20(1):199. https:\/\/doi.org\/10.1186\/s12933-021-01392-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"604_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101334","volume":"4","author":"Q Wu","year":"2023","unstructured":"Wu Q, Yao Q, Hu T, Yu J, Jiang K, Wan Y, et al. Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2. Cell Rep Med. 2023;4(12):101334. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101334.","journal-title":"Cell Rep Med"},{"issue":"19","key":"604_CR61","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1161\/CIRCULATIONAHA.122.062984","volume":"150","author":"C Panico","year":"2024","unstructured":"Panico C, Felicetta A, Kunderfranco P, Cremonesi M, Salvarani N, Carullo P, et al. Single-cell RNA sequencing reveals metabolic stress-dependent activation of cardiac macrophages in a model of dyslipidemia-induced diastolic dysfunction. Circulation. 2024;150(19):1517\u201332. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062984.","journal-title":"Circulation"},{"issue":"1","key":"604_CR62","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-024-02294-z","volume":"23","author":"DD Wang","year":"2024","unstructured":"Wang DD, Naumova AV, Isquith D, Sapp J, Huynh KA, Tucker I, et al. Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure. Cardiovasc Diabetol. 2024;23(1):197. https:\/\/doi.org\/10.1186\/s12933-024-02294-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"604_CR63","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12933-023-01904-6","volume":"22","author":"M Benedikt","year":"2023","unstructured":"Benedikt M, Mangge H, Aziz F, Curcic P, Pailer S, Herrmann M, et al. Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial. Cardiovasc Diabetol. 2023;22(1):166. https:\/\/doi.org\/10.1186\/s12933-023-01904-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"604_CR64","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee S-G, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127. https:\/\/doi.org\/10.1038\/s41467-020-15983-6.","journal-title":"Nat Commun"},{"issue":"1","key":"604_CR65","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100909RR","volume":"36","author":"Q Ke","year":"2022","unstructured":"Ke Q, Shi C, Lv Y, Wang L, Luo J, Jiang L, et al. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney. FASEB J. 2022;36(1):e22078. https:\/\/doi.org\/10.1096\/fj.202100909RR.","journal-title":"FASEB J"},{"issue":"8","key":"604_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101690","volume":"5","author":"H Hu","year":"2024","unstructured":"Hu H, Li W, Hao Y, Peng Z, Zou Z, Wei J, et al. The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy. Cell Rep Med. 2024;5(8):101690. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101690.","journal-title":"Cell Rep Med"},{"issue":"1","key":"604_CR67","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12933-024-02366-0","volume":"23","author":"Y Shi","year":"2024","unstructured":"Shi Y, Zhao L, Wang J, Liu X, Bai Y, Cong H, et al. Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis. Cardiovasc Diabetol. 2024;23(1):269. https:\/\/doi.org\/10.1186\/s12933-024-02366-0.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"604_CR68","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200243R","volume":"36","author":"Z Yang","year":"2022","unstructured":"Yang Z, Li T, Xian J, Chen J, Huang Y, Zhang Q, et al. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2\u03b1 signaling pathway in arrhythmogenic cardiomyopathy. FASEB J. 2022;36(7):e22410. https:\/\/doi.org\/10.1096\/fj.202200243R.","journal-title":"FASEB J"},{"issue":"1","key":"604_CR69","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021;20(1):150. https:\/\/doi.org\/10.1186\/s12933-021-01346-y.","journal-title":"Cardiovasc Diabetol"},{"key":"604_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109024","volume":"110","author":"Q Long","year":"2022","unstructured":"Long Q, Li L, Yang H, Lu Y, Yang H, Zhu Y, et al. SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. Int Immunopharmacol. 2022;110:109024. https:\/\/doi.org\/10.1016\/j.intimp.2022.109024.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"604_CR71","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ejhf.3101","volume":"26","author":"JP Ferreira","year":"2024","unstructured":"Ferreira JP, Butler J, Anker SD, Januzzi JL, Panova-Noeva M, Reese-Petersen AL, et al. Effects of empagliflozin on collagen biomarkers in patients with heart failure: findings from the EMPEROR trials. Eur J Heart Fail. 2024;26(2):274\u201384. https:\/\/doi.org\/10.1002\/ejhf.3101.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"604_CR72","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ekir.2023.11.020","volume":"9","author":"TS Ahluwalia","year":"2024","unstructured":"Ahluwalia TS, R\u00f6nkk\u00f6 TKE, Eickhoff MK, Curovic VR, Siwy J, Eder S, et al. Randomized trial of SGLT2 inhibitor identifies target proteins in diabetic kidney disease. Kidney Int Rep. 2024;9(2):334\u201346. https:\/\/doi.org\/10.1016\/j.ekir.2023.11.020.","journal-title":"Kidney Int Rep"},{"key":"604_CR73","doi-asserted-by":"publisher","first-page":"12260","DOI":"10.1038\/ncomms12260","volume":"7","author":"O Kanisicak","year":"2016","unstructured":"Kanisicak O, Khalil H, Ivey MJ, Karch J, Maliken BD, Correll RN, et al. Genetic lineage tracing defines myofibroblast origin and function in the injured heart. Nat Commun. 2016;7:12260. https:\/\/doi.org\/10.1038\/ncomms12260.","journal-title":"Nat Commun"},{"issue":"6","key":"604_CR74","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","volume":"117","author":"NG Frangogiannis","year":"2021","unstructured":"Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117(6):1450\u201388. https:\/\/doi.org\/10.1093\/cvr\/cvaa324.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"604_CR75","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm1613","volume":"13","author":"EM Zeisberg","year":"2007","unstructured":"Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13(8):952\u201361. https:\/\/doi.org\/10.1038\/nm1613.","journal-title":"Nat Med"},{"issue":"2","key":"604_CR76","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jacc.2018.09.089","volume":"73","author":"JC Kovacic","year":"2019","unstructured":"Kovacic JC, Dimmeler S, Harvey RP, Finkel T, Aikawa E, Krenning G, et al. Endothelial to mesenchymal transition in cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(2):190\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.089.","journal-title":"J Am Coll Cardiol"},{"key":"604_CR77","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1146\/annurev-physiol-032222-080806","volume":"85","author":"Y Xu","year":"2023","unstructured":"Xu Y, Kovacic JC. Endothelial to mesenchymal transition in health and disease. Annu Rev Physiol. 2023;85:245\u201367. https:\/\/doi.org\/10.1146\/annurev-physiol-032222-080806.","journal-title":"Annu Rev Physiol"},{"key":"604_CR78","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57920","volume":"9","author":"L Alonso-Herranz","year":"2020","unstructured":"Alonso-Herranz L, Sahun-Espanol A, Paredes A, Gonzalo P, Gkontra P, Nunez V, et al. Macrophages promote endothelial-to-mesenchymal transition via MT1-MMP\/TGFbeta1 after myocardial infarction. Elife. 2020;9:e57920. https:\/\/doi.org\/10.7554\/eLife.57920.","journal-title":"Elife"},{"issue":"7","key":"604_CR79","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.cmet.2023.05.010","volume":"35","author":"X Zhu","year":"2023","unstructured":"Zhu X, Wang Y, Soaita I, Lee H-W, Bae H, Boutagy N, et al. Acetate controls endothelial-to-mesenchymal transition. Cell Metab. 2023;35(7):1163-1178.e10. https:\/\/doi.org\/10.1016\/j.cmet.2023.05.010.","journal-title":"Cell Metab"},{"key":"604_CR80","doi-asserted-by":"publisher","unstructured":"Fan M, Yang K, Wang X, Chen L, Gill PS, Ha T, et al. Lactate promotes endothelial-to-mesenchymal transition via Snail1 lactylation after myocardial infarction. Sci Adv. 2023;9(5):eadc9465. https:\/\/doi.org\/10.1126\/sciadv.adc9465.","DOI":"10.1126\/sciadv.adc9465"},{"issue":"1","key":"604_CR81","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00395-023-00997-0","volume":"118","author":"P Reventun","year":"2023","unstructured":"Reventun P, S\u00e1nchez-Esteban S, Cook-Calvete A, Delgado-Mar\u00edn M, Roza C, Jorquera-Ortega S, et al. Endothelial ILK induces cardioprotection by preventing coronary microvascular dysfunction and endothelial-to-mesenchymal transition. Basic Res Cardiol. 2023;118(1):28. https:\/\/doi.org\/10.1007\/s00395-023-00997-0.","journal-title":"Basic Res Cardiol"},{"key":"604_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.616610","volume":"9","author":"J Ma","year":"2021","unstructured":"Ma J, van der Zon G, Gon\u00e7alves MAFV, van Dinther M, Thorikay M, Sanchez-Duffhues G, et al. TGF-\u03b2-induced endothelial to mesenchymal transition is determined by a balance between SNAIL and ID factors. Front Cell Dev Biol. 2021;9:616610. https:\/\/doi.org\/10.3389\/fcell.2021.616610.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"604_CR83","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023695","volume":"11","author":"Z Alvandi","year":"2022","unstructured":"Alvandi Z, Nagata Y, Passos LSA, Hashemi Gheinani A, Guerrero JL, Wylie-Sears J, et al. Wnt site signaling inhibitor secreted frizzled-related protein 3 protects mitral valve endothelium from myocardial infarction-induced endothelial-to-mesenchymal transition. J Am Heart Assoc. 2022;11(7):e023695. https:\/\/doi.org\/10.1161\/JAHA.121.023695.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"604_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0273542","volume":"17","author":"Z-Y Zhang","year":"2022","unstructured":"Zhang Z-Y, Zhai C, Yang X-Y, Li H-B, Wu L-L, Li L. Knockdown of CD146 promotes endothelial-to-mesenchymal transition via Wnt\/\u03b2-catenin pathway. PLoS ONE. 2022;17(8):e0273542. https:\/\/doi.org\/10.1371\/journal.pone.0273542.","journal-title":"PLoS ONE"},{"issue":"16","key":"604_CR85","doi-asserted-by":"publisher","first-page":"7642","DOI":"10.1111\/jcmm.16601","volume":"25","author":"J Tian","year":"2021","unstructured":"Tian J, Zhang M, Suo M, Liu D, Wang X, Liu M, et al. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats. J Cell Mol Med. 2021;25(16):7642\u201359. https:\/\/doi.org\/10.1111\/jcmm.16601.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"604_CR86","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","volume":"20","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Lin X, Chu Y, Chen X, Du H, Zhang H, et al. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFbeta1\/Smad signaling. Cardiovasc Diabetol. 2021;20(1):121. https:\/\/doi.org\/10.1186\/s12933-021-01312-8.","journal-title":"Cardiovasc Diabetol"},{"key":"604_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.873108","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Yang Q, Bai W, Yao W, Liu L, Xing Y, et al. Dapagliflozin attenuates myocardial fibrosis by inhibiting the TGF-beta1\/Smad signaling pathway in a normoglycemic rabbit model of chronic heart failure. Front Pharmacol. 2022;13:873108. https:\/\/doi.org\/10.3389\/fphar.2022.873108.","journal-title":"Front Pharmacol"},{"issue":"1","key":"604_CR88","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12933-023-02040-x","volume":"22","author":"W Wang","year":"2023","unstructured":"Wang W, Li Y, Zhang Y, Ye T, Wang K, Li S, et al. SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1. Cardiovasc Diabetol. 2023;22(1):331. https:\/\/doi.org\/10.1186\/s12933-023-02040-x.","journal-title":"Cardiovasc Diabetol"},{"key":"604_CR89","doi-asserted-by":"publisher","first-page":"1499542","DOI":"10.3389\/fphar.2024.1499542","volume":"15","author":"X Yuan","year":"2024","unstructured":"Yuan X, Pan L, Zhang C, Zhu Q, Huang Z, Qin Y, et al. Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt\/beta-catenin signaling pathway. Front Pharmacol. 2024;15:1499542. https:\/\/doi.org\/10.3389\/fphar.2024.1499542.","journal-title":"Front Pharmacol"},{"issue":"10","key":"604_CR90","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","volume":"61","author":"T Rieg","year":"2018","unstructured":"Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61(10):2079\u201386. https:\/\/doi.org\/10.1007\/s00125-018-4654-7.","journal-title":"Diabetologia"},{"issue":"1","key":"604_CR91","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.121.054442","volume":"144","author":"B Pitt","year":"2021","unstructured":"Pitt B, Bhatt DL. Does SGLT1 inhibition add benefit to SGLT2 inhibition in type 2 diabetes? Circulation. 2021;144(1):4\u20136. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054442.","journal-title":"Circulation"},{"issue":"2","key":"604_CR92","doi-asserted-by":"publisher","first-page":"H838","DOI":"10.1152\/ajpheart.00736.2019","volume":"320","author":"L Fert\u00e9","year":"2021","unstructured":"Fert\u00e9 L, Marino A, Battault S, Bultot L, Van Steenbergen A, Bol A, et al. New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans. Am J Physiol Heart Circ Physiol. 2021;320(2):H838\u201353. https:\/\/doi.org\/10.1152\/ajpheart.00736.2019.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"604_CR93","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/cvr\/cvae257","volume":"121","author":"A Mroueh","year":"2025","unstructured":"Mroueh A, Algara-Suarez P, Fakih W, Gong D-S, Matsushita K, Park S-H, et al. SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance. Cardiovasc Res. 2025;121(4):643\u201357. https:\/\/doi.org\/10.1093\/cvr\/cvae257.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"604_CR94","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10557-021-07291-y","volume":"36","author":"B Pitt","year":"2022","unstructured":"Pitt B, Steg G, Leiter LA, Bhatt DL. The role of combined SGLT1\/SGLT2 inhibition in reducing the incidence of stroke and myocardial infarction in patients with type 2 diabetes mellitus. Cardiovasc Drugs Ther. 2022;36(3):561\u20137. https:\/\/doi.org\/10.1007\/s10557-021-07291-y.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"604_CR95","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00395-025-01136-7","volume":"120","author":"Z Li","year":"2025","unstructured":"Li Z, Freiberg S, Music ML, Gu L, Nacos S, Phillips JP, et al. Cardiac sodium-glucose co-transporter 1 (SGLT1) contributes to heart failure in a mouse model of diabetic cardiomyopathy. Basic Res Cardiol. 2025;120(6):1193\u2013207. https:\/\/doi.org\/10.1007\/s00395-025-01136-7.","journal-title":"Basic Res Cardiol"},{"issue":"7892","key":"604_CR96","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41586-021-04212-9","volume":"601","author":"Y Niu","year":"2022","unstructured":"Niu Y, Liu R, Guan C, Zhang Y, Chen Z, Hoerer S, et al. Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter. Nature. 2022;601(7892):280\u20134. https:\/\/doi.org\/10.1038\/s41586-021-04212-9.","journal-title":"Nature"},{"issue":"7892","key":"604_CR97","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-021-04211-w","volume":"601","author":"L Han","year":"2022","unstructured":"Han L, Qu Q, Aydin D, Panova O, Robertson MJ, Xu Y, et al. Structure and mechanism of the SGLT family of glucose transporters. Nature. 2022;601(7892):274\u20139. https:\/\/doi.org\/10.1038\/s41586-021-04211-w.","journal-title":"Nature"},{"issue":"1","key":"604_CR98","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41467-025-62421-6","volume":"16","author":"W Cui","year":"2025","unstructured":"Cui W, Sun Z, Xu J, Liu X, Kang Y, Chen L. Mechanism of substrate recognition and release of human SGLT2. Nat Commun. 2025;16(1):7140. https:\/\/doi.org\/10.1038\/s41467-025-62421-6.","journal-title":"Nat Commun"},{"issue":"1","key":"604_CR99","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1038\/s41467-023-38720-1","volume":"14","author":"W Cui","year":"2023","unstructured":"Cui W, Niu Y, Sun Z, Liu R, Chen L. Structures of human SGLT in the occluded state reveal conformational changes during sugar transport. Nat Commun. 2023;14(1):2920. https:\/\/doi.org\/10.1038\/s41467-023-38720-1.","journal-title":"Nat Commun"},{"issue":"1","key":"604_CR100","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/dmrr.532","volume":"21","author":"JRL Ehrenkranz","year":"2005","unstructured":"Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31\u20138. https:\/\/doi.org\/10.1002\/dmrr.532.","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"604_CR101","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41594-023-01134-0","volume":"31","author":"M Hiraizumi","year":"2024","unstructured":"Hiraizumi M, Akashi T, Murasaki K, Kishida H, Kumanomidou T, Torimoto N, et al. Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter. Nat Struct Mol Biol. 2024;31(1):159\u201369. https:\/\/doi.org\/10.1038\/s41594-023-01134-0.","journal-title":"Nat Struct Mol Biol"},{"issue":"14","key":"604_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146937","volume":"26","author":"T Mateoc","year":"2025","unstructured":"Mateoc T, Dumitrascu AL, Flangea C, Puscasiu D, Vlad T, Popescu R, et al. SGLT2 inhibitors: from structure-effect relationship to pharmacological response. Int J Mol Sci. 2025;26(14):6937. https:\/\/doi.org\/10.3390\/ijms26146937.","journal-title":"Int J Mol Sci"},{"key":"604_CR103","doi-asserted-by":"publisher","first-page":"1668400","DOI":"10.3389\/fmolb.2025.1668400","volume":"12","author":"N Kaijage","year":"2025","unstructured":"Kaijage N, Kraszewski S. Molecular mechanisms and computational insights into human SGLTs: advancing toward selective SGLT1 inhibition. Front Mol Biosci. 2025;12:1668400. https:\/\/doi.org\/10.3389\/fmolb.2025.1668400.","journal-title":"Front Mol Biosci"},{"issue":"2","key":"604_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/ph19020246","volume":"19","author":"Z Chen","year":"2026","unstructured":"Chen Z, Tan K, Shi Y, Liu M, Yi L, Chen T, et al. Computational discovery of novel SGLT2 inhibitors from eight selected medicine food homology herbs using a multi-stage virtual screening pipeline. Pharmaceuticals (Basel). 2026;19(2):246. https:\/\/doi.org\/10.3390\/ph19020246.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"604_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0334656","volume":"20","author":"A Lloyd","year":"2025","unstructured":"Lloyd A, Austin-Muttitt K, Mullins JGL. Computational structural studies of SGLT2-related polypharmacy. PLoS ONE. 2025;20(10):e0334656. https:\/\/doi.org\/10.1371\/journal.pone.0334656.","journal-title":"PLoS ONE"},{"issue":"7","key":"604_CR106","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","volume":"54","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015;54(7):691\u2013708. https:\/\/doi.org\/10.1007\/s40262-015-0264-4.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"604_CR107","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","volume":"14","author":"A Garcia-Ropero","year":"2018","unstructured":"Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018;14(12):1287\u2013302. https:\/\/doi.org\/10.1080\/17425255.2018.1551877.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"604_CR108","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3390\/ph17040522","volume":"17","author":"X Jiang","year":"2024","unstructured":"Jiang X, Yu K-S, Nam DH, Oh J. A population pharmacokinetic study to compare a novel empagliflozin L-proline formulation with its conventional formulation in healthy subjects. Pharmaceuticals (Basel). 2024;17(4):522. https:\/\/doi.org\/10.3390\/ph17040522.","journal-title":"Pharmaceuticals (Basel)"},{"key":"604_CR109","doi-asserted-by":"publisher","first-page":"1520268","DOI":"10.3389\/fphar.2025.1520268","volume":"16","author":"G Guo","year":"2025","unstructured":"Guo G, Ke M, Xu J, Wu W, Chen J, Ke C, et al. Physiologically based pharmacokinetic model of sodium-glucose cotransporter 2 inhibitors predicted pharmacokinetics and pharmacodynamics to explore dosage regimen for patients with type 2 diabetes mellitus and renal insufficiency. Front Pharmacol. 2025;16:1520268. https:\/\/doi.org\/10.3389\/fphar.2025.1520268.","journal-title":"Front Pharmacol"},{"issue":"1","key":"604_CR110","doi-asserted-by":"publisher","first-page":"24695","DOI":"10.1038\/s41598-024-76256-6","volume":"14","author":"H Sato","year":"2024","unstructured":"Sato H, Ishikawa A, Yoshioka H, Jin R, Sano Y, Hisaka A. Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion. Sci Rep. 2024;14(1):24695. https:\/\/doi.org\/10.1038\/s41598-024-76256-6.","journal-title":"Sci Rep"},{"issue":"22","key":"604_CR111","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"2","key":"604_CR112","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"10354","key":"604_CR113","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(22)01429-5.","journal-title":"Lancet"},{"issue":"7","key":"604_CR114","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"issue":"4","key":"604_CR115","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"3","key":"604_CR116","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","volume":"99","author":"BJ Kraus","year":"2021","unstructured":"Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, et al. Characterization and implications of the initial estimated glomerular filtration rate \u201cdip\u201d upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021;99(3):750\u201362. https:\/\/doi.org\/10.1016\/j.kint.2020.10.031.","journal-title":"Kidney Int"},{"issue":"1","key":"604_CR117","doi-asserted-by":"publisher","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","volume":"316","author":"A Novikov","year":"2019","unstructured":"Novikov A, Fu Y, Huang W, Freeman B, Patel R, van Ginkel C, et al. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Renal Physiol. 2019;316(1):F173\u201385. https:\/\/doi.org\/10.1152\/ajprenal.00462.2018.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"604_CR118","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","volume":"83","author":"M Packer","year":"2024","unstructured":"Packer M. Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure: JACC review topic of the week. J Am Coll Cardiol. 2024;83(2):371\u201381. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.030.","journal-title":"J Am Coll Cardiol"},{"key":"604_CR119","doi-asserted-by":"publisher","first-page":"1667438","DOI":"10.3389\/fendo.2025.1667438","volume":"16","author":"EA Habeeb","year":"2025","unstructured":"Habeeb EA, Ghaith AM, Alshehri AM, Aquil G, Afana AH, Alqarafi AH, et al. Revealing the hidden impact of SGLT2 inhibitors on uric acid levels: a retrospective multicenter cohort study. Front Endocrinol (Lausanne). 2025;16:1667438. https:\/\/doi.org\/10.3389\/fendo.2025.1667438.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"604_CR120","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356\u201363. https:\/\/doi.org\/10.2337\/dc17-1096.","journal-title":"Diabetes Care"},{"issue":"2","key":"604_CR121","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ejhf.2735","volume":"25","author":"C Fuchs Andersen","year":"2023","unstructured":"Fuchs Andersen C, Omar M, Glenth\u00f8j A, El Fassi D, M\u00f8ller HJ, Lindholm Kurtzhals JA, et al. Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial. Eur J Heart Fail. 2023;25(2):226\u201334. https:\/\/doi.org\/10.1002\/ejhf.2735.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"604_CR122","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jamainternmed.2024.7357","volume":"185","author":"H Shin","year":"2025","unstructured":"Shin H, Paik JM, Everett BM, DiCesare E, Alix C, Glynn RJ, et al. Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors. JAMA Intern Med. 2025;185(3):302\u201313. https:\/\/doi.org\/10.1001\/jamainternmed.2024.7357.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"604_CR123","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1053\/j.ajkd.2025.09.022","volume":"87","author":"D Zhu","year":"2026","unstructured":"Zhu D, Judge PK, Francis ST, Che Z, Rayner JJ, Buchanan C, et al. Effects of empagliflozin on kidney and cardiac magnetic resonance imaging measures in patients with CKD: an EMPA-KIDNEY mechanistic substudy. Am J Kidney Dis. 2026;87(4):564\u20138. https:\/\/doi.org\/10.1053\/j.ajkd.2025.09.022.","journal-title":"Am J Kidney Dis"},{"issue":"12 Pt 2","key":"604_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102304","volume":"4","author":"AT Reutens","year":"2025","unstructured":"Reutens AT, Lekamlage DH, Salim A, Shaw JE, Esler MD, Cooper ME, et al. Effect of empagliflozin on whole body, cardiac, and renal sympathetic outflows in type 2 diabetes. JACC Adv. 2025;4(12 Pt 2):102304. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102304.","journal-title":"JACC Adv"},{"issue":"18","key":"604_CR125","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2025.03.503","volume":"85","author":"JP Ferreira","year":"2025","unstructured":"Ferreira JP, Anker SD, Butler J, Filippatos G, Januzzi JL, Schueler E, et al. Effect of empagliflozin on the mechanisms driving erythropoiesis and iron mobilization in patients with heart failure: the EMPEROR program. J Am Coll Cardiol. 2025;85(18):1757\u201370. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.503.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"604_CR126","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/dom.15464","volume":"26","author":"L Vernstr\u00f8m","year":"2024","unstructured":"Vernstr\u00f8m L, Gullaksen S, S\u00f8rensen SS, Funck KL, Laugesen E, Poulsen PL. Separate and combined effects of empagliflozin and semaglutide on vascular function: a 32-week randomized trial. Diabetes Obes Metab. 2024;26(5):1624\u201335. https:\/\/doi.org\/10.1111\/dom.15464.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"604_CR127","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","volume":"79","author":"P Mone","year":"2022","unstructured":"Mone P, Varzideh F, Jankauskas SS, Pansini A, Lombardi A, Frullone S, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension. 2022;79(8):1633\u201343. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19586.","journal-title":"Hypertension"},{"issue":"6","key":"604_CR128","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1091581814551648","volume":"33","author":"MS Bogdanffy","year":"2014","unstructured":"Bogdanffy MS, Stachlewitz RF, van Tongeren S, Knight B, Sharp DE, Ku W, et al. Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin. Int J Toxicol. 2014;33(6):436\u201349. https:\/\/doi.org\/10.1177\/1091581814551648.","journal-title":"Int J Toxicol"},{"key":"604_CR129","doi-asserted-by":"publisher","first-page":"1215356","DOI":"10.3389\/fendo.2023.1215356","volume":"14","author":"DRP Muller","year":"2023","unstructured":"Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne). 2023;14:1215356. https:\/\/doi.org\/10.3389\/fendo.2023.1215356.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"15","key":"604_CR130","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2004967.","journal-title":"N Engl J Med"},{"issue":"3","key":"604_CR131","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","volume":"183","author":"E D'Andrea","year":"2023","unstructured":"D\u2019Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E. Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels. JAMA Intern Med. 2023;183(3):242\u201354. https:\/\/doi.org\/10.1001\/jamainternmed.2022.6664.","journal-title":"JAMA Intern Med"},{"issue":"7","key":"604_CR132","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(20)30130-3","volume":"8","author":"S Kohsaka","year":"2020","unstructured":"Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, J\u00f8rgensen ME, et al. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes Endocrinol. 2020;8(7):606\u201315. https:\/\/doi.org\/10.1016\/S2213-8587(20)30130-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"25","key":"604_CR133","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.119.045561","volume":"141","author":"M Packer","year":"2020","unstructured":"Packer M. Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance. Circulation. 2020;141(25):2095\u2013105. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.045561.","journal-title":"Circulation"},{"issue":"2","key":"604_CR134","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2030186.","journal-title":"N Engl J Med"},{"issue":"2","key":"604_CR135","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa2030183.","journal-title":"N Engl J Med"},{"issue":"24","key":"604_CR136","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"6","key":"604_CR137","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2215\/CJN.0000000000000161","volume":"18","author":"S van der Hoek","year":"2023","unstructured":"van der Hoek S, Jongs N, Oshima M, Neuen BL, Stevens J, Perkovic V, et al. Glycemic control and effects of canagliflozin in reducing albuminuria and eGFR: a post hoc analysis of the CREDENCE trial. Clin J Am Soc Nephrol. 2023;18(6):748\u201358. https:\/\/doi.org\/10.2215\/CJN.0000000000000161.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"604_CR138","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"1","key":"604_CR139","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22\u201331. https:\/\/doi.org\/10.1016\/S2213-8587(20)30369-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"604_CR140","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215\u201324. https:\/\/doi.org\/10.1016\/j.kint.2021.03.033.","journal-title":"Kidney Int"},{"issue":"1","key":"604_CR141","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","unstructured":"EMPA-KIDNEY Collaborative Group. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12(1):39\u201350. https:\/\/doi.org\/10.1016\/S2213-8587(23)00321-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"604_CR142","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(21)00242-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"604_CR143","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755\u201366. https:\/\/doi.org\/10.1016\/S2213-8587(21)00243-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"604_CR144","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","volume":"32","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol. 2021;32(9):2352\u201361. https:\/\/doi.org\/10.1681\/ASN.2021020167.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"604_CR145","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1681\/ASN.0000000000000466","volume":"35","author":"WM Bakker","year":"2024","unstructured":"Bakker WM, Gansevoort RT, Yang C, Chertow GM, Heerspink HJL, Vart P. Sodium-Glucose cotransporter 2 inhibitors in older patients with CKD. J Am Soc Nephrol. 2024;35(10):1446\u20139. https:\/\/doi.org\/10.1681\/ASN.0000000000000466.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"604_CR146","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.2337\/dc21-1081","volume":"44","author":"H Nagasu","year":"2021","unstructured":"Nagasu H, Yano Y, Kanegae H, Heerspink HJL, Nangaku M, Hirakawa Y, et al. Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan Chronic Kidney Disease Database. Diabetes Care. 2021;44(11):2542\u201351. https:\/\/doi.org\/10.2337\/dc21-1081.","journal-title":"Diabetes Care"},{"issue":"8","key":"604_CR147","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2409183","volume":"392","author":"WG Herrington","year":"2025","unstructured":"Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, et al. Long-term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med. 2025;392(8):777\u201387. https:\/\/doi.org\/10.1056\/NEJMoa2409183.","journal-title":"N Engl J Med"},{"issue":"21","key":"604_CR148","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"10254","key":"604_CR149","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9.","journal-title":"Lancet"},{"issue":"16","key":"604_CR150","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"12","key":"604_CR151","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"issue":"15","key":"604_CR152","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"4","key":"604_CR153","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation. 2021;143(4):326\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051783.","journal-title":"Circulation"},{"issue":"13","key":"604_CR154","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","volume":"42","author":"J Butler","year":"2021","unstructured":"Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021;42(13):1203\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1007.","journal-title":"Eur Heart J"},{"issue":"14","key":"604_CR155","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohl\u00e1vek J, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353\u201368. https:\/\/doi.org\/10.1001\/jama.2020.1906.","journal-title":"JAMA"},{"issue":"4","key":"604_CR156","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","volume":"143","author":"PS Jhund","year":"2021","unstructured":"Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, B\u00f6hm M, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021;143(4):298\u2013309. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050391.","journal-title":"Circulation"},{"issue":"6","key":"604_CR157","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/circulationaha.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516\u201325. https:\/\/doi.org\/10.1161\/circulationaha.120.052186.","journal-title":"Circulation"},{"issue":"21","key":"604_CR158","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140(21):1693\u2013702. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042375.","journal-title":"Circulation"},{"issue":"3","key":"604_CR159","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.008.","journal-title":"J Am Coll Cardiol"},{"key":"604_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.906272","volume":"13","author":"L Cornuault","year":"2022","unstructured":"Cornuault L, Rouault P, Dupl\u00e0a C, Couffinhal T, Renault M-A. Endothelial dysfunction in heart failure with preserved ejection fraction: what are the experimental proofs? Front Physiol. 2022;13:906272. https:\/\/doi.org\/10.3389\/fphys.2022.906272.","journal-title":"Front Physiol"},{"issue":"6","key":"604_CR161","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamacardio.2023.0711","volume":"8","author":"PS Jhund","year":"2023","unstructured":"Jhund PS, Claggett BL, Talebi A, Butt JH, Gasparyan SB, Wei L-J, et al. Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER trial. JAMA Cardiol. 2023;8(6):554\u201363. https:\/\/doi.org\/10.1001\/jamacardio.2023.0711.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"604_CR162","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954\u201360. https:\/\/doi.org\/10.1038\/s41591-021-01536-x.","journal-title":"Nat Med"},{"issue":"4","key":"604_CR163","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA, Birmingham MC, Nassif M, Damaraju CV, Abbate A, Butler J, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809\u201313. https:\/\/doi.org\/10.1038\/s41591-022-01703-8.","journal-title":"Nat Med"},{"issue":"3","key":"604_CR164","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","volume":"145","author":"J Butler","year":"2022","unstructured":"Butler J, Filippatos G, Jamal Siddiqi T, Brueckmann M, B\u00f6hm M, Chopra VK, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial. Circulation. 2022;145(3):184\u201393. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057812.","journal-title":"Circulation"},{"issue":"8 Pt 1","key":"604_CR165","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jchf.2023.05.026","volume":"11","author":"B Pitt","year":"2023","unstructured":"Pitt B, Bhatt DL, Szarek M, Cannon CP, Leiter LA, McGuire DK, et al. Effect of sotagliflozin on early mortality and heart failure-related events: a post hoc analysis of SOLOIST-WHF. JACC Heart Fail. 2023;11(8 Pt 1):879\u201389. https:\/\/doi.org\/10.1016\/j.jchf.2023.05.026.","journal-title":"JACC Heart Fail"},{"issue":"8","key":"604_CR166","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.7326\/M21-0651","volume":"174","author":"M Szarek","year":"2021","unstructured":"Szarek M, Bhatt DL, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure\u202f: a randomized trial. Ann Intern Med. 2021;174(8):1065\u201372. https:\/\/doi.org\/10.7326\/M21-0651.","journal-title":"Ann Intern Med"},{"issue":"14","key":"604_CR167","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","volume":"83","author":"ZL Cox","year":"2024","unstructured":"Cox ZL, Collins SP, Hernandez GA, McRae AT, Davidson BT, Adams K, et al. Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol. 2024;83(14):1295\u2013306. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.009.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"604_CR168","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.125.076575","volume":"152","author":"DD Berg","year":"2025","unstructured":"Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, et al. Dapagliflozin in patients hospitalized for heart failure: primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of sodium-glucose cotransporter-2 inhibitors in patients hospitalized for heart failure. Circulation. 2025;152(20):1411\u201322. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.076575.","journal-title":"Circulation"},{"issue":"9","key":"604_CR169","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/ejhf.2584","volume":"24","author":"D Vukadinovi\u0107","year":"2022","unstructured":"Vukadinovi\u0107 D, Abdin A, Anker SD, Rosano GMC, Mahfoud F, Packer M, et al. Side effects and treatment initiation barriers of sodium\u2013glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24(9):1625\u201332. https:\/\/doi.org\/10.1002\/ejhf.2584.","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"604_CR170","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390(16):1455\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2314051.","journal-title":"N Engl J Med"},{"issue":"21","key":"604_CR171","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","volume":"149","author":"AF Hernandez","year":"2024","unstructured":"Hernandez AF, Udell JA, Jones WS, Anker SD, Petrie MC, Harrington J, et al. Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial. Circulation. 2024;149(21):1627\u201338. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069217.","journal-title":"Circulation"},{"issue":"5","key":"604_CR172","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/ehjcvp\/pvaf040","volume":"11","author":"D Fedele","year":"2025","unstructured":"Fedele D, Casuso Alvarez M, Maida A, Vasumini N, Amicone S, Canton L, et al. Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2025;11(5):441\u201350. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf040.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"13","key":"604_CR173","doi-asserted-by":"publisher","DOI":"10.1172\/jci142548","volume":"132","author":"Y-J Lai","year":"2022","unstructured":"Lai Y-J, Tsai F-C, Chang G-J, Chang S-H, Huang C-C, Chen W-J, et al. miR-181b targets semaphorin 3A to mediate TGF-\u03b2\u2013induced endothelial-mesenchymal transition related to atrial fibrillation. J Clin Invest. 2022;132(13):e142548. https:\/\/doi.org\/10.1172\/jci142548.","journal-title":"J Clin Invest"},{"key":"604_CR174","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735.","journal-title":"BMJ"},{"key":"604_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101553","volume":"64","author":"C Cai","year":"2022","unstructured":"Cai C, Wu F, Zhuang B, Ou Q, Peng X, Shi N, et al. Empagliflozin activates Wnt\/\u03b2-catenin to stimulate FUNDC1-dependent mitochondrial quality surveillance against type-3 cardiorenal syndrome. Mol Metab. 2022;64:101553. https:\/\/doi.org\/10.1016\/j.molmet.2022.101553.","journal-title":"Mol Metab"},{"issue":"1","key":"604_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02655-2","volume":"24","author":"W Wang","year":"2025","unstructured":"Wang W, Liu Y, Xu Q, Liu L, Zhu M, Li Y, et al. Cellular crosstalk in organotypic vasculature: mechanisms of diabetic cardiorenal complications and SGLT2i responses. Cardiovasc Diabetol. 2025;24(1):90. https:\/\/doi.org\/10.1186\/s12933-025-02655-2.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"604_CR177","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S2213-8587(24)00362-0","volume":"13","author":"R Aggarwal","year":"2025","unstructured":"Aggarwal R, Bhatt DL, Szarek M, Cannon CP, Leiter LA, Inzucchi SE, et al. Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial. Lancet Diabetes Endocrinol. 2025;13(4):321\u201332. https:\/\/doi.org\/10.1016\/S2213-8587(24)00362-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"604_CR178","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.125.323916","volume":"46","author":"KC Muir","year":"2026","unstructured":"Muir KC, Stone C, Reddy R, Kanuparthy M, Hamze J, Harris DD, et al. Sotagliflozin enhances left ventricular function and myocardial perfusion in chronic myocardial ischemia through metabolic and redox remodeling. Arterioscler Thromb Vasc Biol. 2026;46(2):e323916. https:\/\/doi.org\/10.1161\/ATVBAHA.125.323916.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"604_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22423","volume":"9","author":"P Zhong","year":"2023","unstructured":"Zhong P, Zhang J, Wei Y, Liu T, Chen M. Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats. Heliyon. 2023;9(11):e22423. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22423.","journal-title":"Heliyon"},{"key":"604_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106598","volume":"199","author":"L Liao","year":"2024","unstructured":"Liao L, Zhang L, Yang C, Wang T, Feng L, Peng C, et al. Sotagliflozin attenuates cardiac dysfunction and depression-like behaviors in mice with myocardial infarction through the gut-heart-brain axis. Neurobiol Dis. 2024;199:106598. https:\/\/doi.org\/10.1016\/j.nbd.2024.106598.","journal-title":"Neurobiol Dis"},{"issue":"16","key":"604_CR181","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1136\/heartjnl-2022-322181","volume":"109","author":"Y Sotomi","year":"2023","unstructured":"Sotomi Y, Hikoso S, Nakatani D, Okada K, Dohi T, Sunaga A, et al. Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model. Heart. 2023;109(16):1231\u201340. https:\/\/doi.org\/10.1136\/heartjnl-2022-322181.","journal-title":"Heart"},{"issue":"9","key":"604_CR182","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687\u201393. https:\/\/doi.org\/10.2337\/dc15-0843.","journal-title":"Diabetes Care"},{"issue":"8","key":"604_CR183","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1210\/jc.2019-00139","volume":"104","author":"PS Hamblin","year":"2019","unstructured":"Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019;104(8):3077\u201387. https:\/\/doi.org\/10.1210\/jc.2019-00139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"604_CR184","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","volume":"173","author":"A Douros","year":"2020","unstructured":"Douros A, Lix LM, Fralick M, Dell\u2019Aniello S, Shah BR, Ronksley PE, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis\u202f: a multicenter cohort study. Ann Intern Med. 2020;173(6):417\u201325. https:\/\/doi.org\/10.7326\/M20-0289.","journal-title":"Ann Intern Med"},{"issue":"10166","key":"604_CR185","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X.","journal-title":"Lancet"},{"issue":"5S","key":"604_CR186","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"issue":"4","key":"604_CR187","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamasurg.2024.7082","volume":"160","author":"AA Dixit","year":"2025","unstructured":"Dixit AA, Bateman BT, Hawn MT, Odden MC, Sun EC. Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis. JAMA Surg. 2025;160(4):423\u201330. https:\/\/doi.org\/10.1001\/jamasurg.2024.7082.","journal-title":"JAMA Surg"},{"issue":"6","key":"604_CR188","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamasurg.2025.0940","volume":"160","author":"RT Tallarico","year":"2025","unstructured":"Tallarico RT, Jing B, Lu K, Chawla SA, Luo Y, Badathala A, et al. Postoperative outcomes among sodium-glucose cotransporter 2 inhibitor users. JAMA Surg. 2025;160(6):681\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2025.0940.","journal-title":"JAMA Surg"},{"issue":"4","key":"604_CR189","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171(4):248\u201356. https:\/\/doi.org\/10.7326\/M18-3136.","journal-title":"Ann Intern Med"},{"issue":"5","key":"604_CR190","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2215\/CJN.0000000000000115","volume":"18","author":"EL Fu","year":"2023","unstructured":"Fu EL, D\u2019Andrea E, Wexler DJ, Patorno E, Paik JM. Safety of sodium-glucose cotransporter-2 inhibitors in patients with CKD and type 2 diabetes: population-based US cohort study. Clin J Am Soc Nephrol. 2023;18(5):592\u2013601. https:\/\/doi.org\/10.2215\/CJN.0000000000000115.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"604_CR191","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"604_CR192","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M, Eliasson B, Svensson A-M, Franz\u00e9n S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. https:\/\/doi.org\/10.1136\/bmj.k4365.","journal-title":"BMJ"},{"issue":"3","key":"604_CR193","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7326\/M18-0567","volume":"170","author":"M Fralick","year":"2019","unstructured":"Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E. Fracture risk after initiation of use of canagliflozin: a cohort study. Ann Intern Med. 2019;170(3):155\u201363. https:\/\/doi.org\/10.7326\/M18-0567.","journal-title":"Ann Intern Med"},{"issue":"1","key":"604_CR194","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12933-025-02904-4","volume":"24","author":"I Leo","year":"2025","unstructured":"Leo I, Salerno N, Figliozzi S, Cersosimo A, Ielapi J, Stankowski K, et al. Effect of SGLT2 inhibitors on cardiac structure and function assessed by cardiac magnetic resonance: a systematic review and meta-analysis. Cardiovasc Diabetol. 2025;24(1):345. https:\/\/doi.org\/10.1186\/s12933-025-02904-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"604_CR195","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1186\/s40001-025-02834-7","volume":"30","author":"A Albulushi","year":"2025","unstructured":"Albulushi A, Askari KM, Al-Abedi AM, Al-Kulaibi MA, Hasan MS, Hosseini Z, et al. Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study. Eur J Med Res. 2025;30(1):592. https:\/\/doi.org\/10.1186\/s40001-025-02834-7.","journal-title":"Eur J Med Res"},{"issue":"1","key":"604_CR196","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41467-021-20905-1","volume":"12","author":"LS Tombor","year":"2021","unstructured":"Tombor LS, John D, Glaser SF, Lux\u00e1n G, Forte E, Furtado M, et al. Single cell sequencing reveals endothelial plasticity with transient mesenchymal activation after myocardial infarction. Nat Commun. 2021;12(1):681. https:\/\/doi.org\/10.1038\/s41467-021-20905-1.","journal-title":"Nat Commun"},{"issue":"3","key":"604_CR197","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/cvr\/cvae021","volume":"120","author":"IF Hall","year":"2024","unstructured":"Hall IF, Kishta F, Xu Y, Baker AH, Kovacic JC. Endothelial to mesenchymal transition: at the axis of cardiovascular health and disease. Cardiovasc Res. 2024;120(3):223\u201336. https:\/\/doi.org\/10.1093\/cvr\/cvae021.","journal-title":"Cardiovasc Res"},{"issue":"12","key":"604_CR198","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1161\/ATVBAHA.120.314789","volume":"40","author":"K Xu","year":"2020","unstructured":"Xu K, Xie S, Huang Y, Zhou T, Liu M, Zhu P, et al. Cell-type transcriptome atlas of human aortic valves reveal cell heterogeneity and endothelial to mesenchymal transition involved in calcific aortic valve disease. Arterioscler Thromb Vasc Biol. 2020;40(12):2910\u201321. https:\/\/doi.org\/10.1161\/ATVBAHA.120.314789.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"604_CR199","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.917761","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Ding L, Tian L, Tian Y, Liao L, Zhao J. Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: a meta-analysis of clinical studies. Front Endocrinol (Lausanne). 2022;13:917761. https:\/\/doi.org\/10.3389\/fendo.2022.917761.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"604_CR200","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jare.2024.02.006","volume":"68","author":"G Li","year":"2025","unstructured":"Li G, Zhao H, Cheng Z, Liu J, Li G, Guo Y. Single-cell transcriptomic profiling of heart reveals ANGPTL4 linking fibroblasts and angiogenesis in heart failure with preserved ejection fraction. J Adv Res. 2025;68:215\u201330. https:\/\/doi.org\/10.1016\/j.jare.2024.02.006.","journal-title":"J Adv Res"},{"issue":"32","key":"604_CR201","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp6182","volume":"10","author":"M Lebas","year":"2024","unstructured":"Lebas M, Chinig\u00f2 G, Courmont E, Bettaieb L, Machmouchi A, Goveia J, et al. Integrated single-cell RNA-seq analysis reveals mitochondrial calcium signaling as a modulator of endothelial-to-mesenchymal transition. Sci Adv. 2024;10(32):eadp6182. https:\/\/doi.org\/10.1126\/sciadv.adp6182.","journal-title":"Sci Adv"},{"issue":"9","key":"604_CR202","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","volume":"28","author":"PS Jhund","year":"2022","unstructured":"Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28(9):1956\u201364. https:\/\/doi.org\/10.1038\/s41591-022-01971-4.","journal-title":"Nat Med"},{"issue":"11","key":"604_CR203","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jchf.2023.05.015","volume":"11","author":"JW Ostrominski","year":"2023","unstructured":"Ostrominski JW, Thierer J, Claggett BL, Miao ZM, Desai AS, Jhund PS, et al. Cardio-renal-metabolic overlap, outcomes, and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC Heart Fail. 2023;11(11):1491\u2013503. https:\/\/doi.org\/10.1016\/j.jchf.2023.05.015.","journal-title":"JACC Heart Fail"},{"issue":"16","key":"604_CR204","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","volume":"146","author":"JH Butt","year":"2022","unstructured":"Butt JH, Jhund PS, Belohl\u00e1vek J, de Boer RA, Chiang C-E, Desai AS, et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation. 2022;146(16):1210\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061754.","journal-title":"Circulation"},{"issue":"41","key":"604_CR205","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","volume":"43","author":"C Adamson","year":"2022","unstructured":"Adamson C, Kondo T, Jhund PS, de Boer RA, Cabrera Honorio JW, Claggett B, et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J. 2022;43(41):4406\u201317. https:\/\/doi.org\/10.1093\/eurheartj\/ehac481.","journal-title":"Eur Heart J"},{"issue":"5","key":"604_CR206","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","volume":"81","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Bhatt AS, Claggett BL, Vaduganathan M, Kulac IJ, Lam CSP, et al. Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol. 2023;81(5):460\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.006.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"604_CR207","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamacardio.2023.4664","volume":"9","author":"FR Mc Causland","year":"2024","unstructured":"Mc Causland FR, Claggett BL, Vaduganathan M, Desai A, Jhund P, Vardeny O, et al. Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol. 2024;9(2):144\u201352. https:\/\/doi.org\/10.1001\/jamacardio.2023.4664.","journal-title":"JAMA Cardiol"},{"issue":"20","key":"604_CR208","doi-asserted-by":"publisher","first-page":"10098","DOI":"10.3390\/ijms262010098","volume":"26","author":"C Baufays","year":"2025","unstructured":"Baufays C, Cumps J, Dufeys C, Ginion A, Bertrand L, Horman S, et al. Comparison of the effects of sodium-glucose cotransporter 2 inhibitors on cardiac fibroblast properties. Int J Mol Sci. 2025;26(20):10098. https:\/\/doi.org\/10.3390\/ijms262010098.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"604_CR209","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.2337\/dc21-2166","volume":"45","author":"MG Posch","year":"2022","unstructured":"Posch MG, Walther N, Ferrannini E, Powell DR, Banks P, Wason S, et al. Metabolic, intestinal, and cardiovascular effects of sotagliflozin compared with empagliflozin in patients with type 2 diabetes: a randomized,\u00a0double-blind study. Diabetes Care. 2022;45(9):2118\u201326. https:\/\/doi.org\/10.2337\/dc21-2166.","journal-title":"Diabetes Care"},{"issue":"6","key":"604_CR210","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024;149(6):450\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067584.","journal-title":"Circulation"},{"issue":"8","key":"604_CR211","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12(8):545\u201357. https:\/\/doi.org\/10.1016\/S2213-8587(24)00155-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"604_CR212","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025;393(6):533\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2410659.","journal-title":"N Engl J Med"},{"issue":"3","key":"604_CR213","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2215\/CJN.0000000902","volume":"21","author":"MF Blum","year":"2026","unstructured":"Blum MF, Mehta S, Surapaneni A, Carrero JJ, Zhang D, Inker L, et al. A target trial emulation study of SGLT2 inhibitors, GLP-1 receptor agonists, and combination therapy in preventing kidney failure in type 2 diabetes. Clin J Am Soc Nephrol. 2026;21(3):437\u201345. https:\/\/doi.org\/10.2215\/CJN.0000000902.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00604-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00604-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00604-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:53:07Z","timestamp":1790808787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00604-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":213,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00604-3","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"191"}}